AbbVie has secured approval and is launching its preventive migraine treatment in the European Union, a major new market. This geographic expansion is a key growth driver for the neuroscience franchise, requiring investment in regional marketing and distribution.
Filing excerpt
Qulipta (atogepant) is a calcitonin gene-related peptide receptor antagonist indicated for the preventive treatment of episodic and chronic migraine in adults. Qulipta is commercialized in the United States and Canada and is approved in the European Union under the brand name Aquipta.
What this signalsFilings often name leadership changes, deals and spending plans.
Regions named
sec-10kmarketExpansionGet every 10-K signal for AbbVie and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at AbbVie this week?”
The Signal API returns 10-K signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-10k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/7d75e58d-b460-436b-bf4e-967c158154ab returns this record as JSON. POST /v1/companies/enrich returns every signal for abbvie.com.
{
"signal_id": "7d75e58d-b460-436b-bf4e-967c158154ab",
"signal_type": "sec-10k",
"signal_subtype": "marketExpansion",
"detected_at": "2026-02-24T09:18:27.385+00:00",
"company": {
"name": "AbbVie",
"domain": "abbvie.com"
},
"data": {
"detail": "AbbVie has secured approval and is launching its preventive migraine treatment in the European Union, a major new market. This geographic expansion is a key growth driver for the neuroscience franchise, requiring investment in regional marketing and distribution.",
"metrics": {
"timeframe": "current_year"
},
"summary": "AbbVie expands migraine drug Qulipta into European Union, rebranded as Aquipta.",
"excerpts": "Qulipta (atogepant) is a calcitonin gene-related peptide receptor antagonist indicated for the preventive treatment of episodic and chronic migraine in adults. Qulipta is commercialized in the United States and Canada and is approved in the European Union under the brand name Aquipta.",
"relevance": 0.9,
"sentiment": "positive",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/1551152/000155115226000008/abbv-20251231.htm",
"filing_date": "2026-02-20",
"filing_year": 2026,
"fiscal_year_end": "12/31",
"sales_relevance": "Scaling infrastructure needed",
"signal_category": "market",
"regions_mentioned": [
"United States",
"Canada",
"European Union"
]
}
}
curl https://signals.autobound.ai/v1/signals/7d75e58d-b460-436b-bf4e-967c158154ab \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"abbvie.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.